Strongbridge Biopharma plc Highlights Publication Of Long-term Efficacy And Safety Results For KEVEYIS For Treatment Of Primary Periodic Paralysis In Muscle & Nerve

Author: Bill Haddad | July 13, 2021 07:37am

Strongbridge Biopharma plc, (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that post hoc analyses from a one year open-label study evaluating daily use of KEVEYIS® (dichlorphenamide) for the treatment of Primary Periodic Paralysis (PPP) following a nine-week randomized, controlled study were published in the peer-reviewed journal, Muscle & Nerve. The results confirmed that long-term treatment with KEVEYIS is safe and effective for chronic use.

Posted In: SBBP